Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions
نویسندگان
چکیده
Hot flashes are one of the most common and distressing symptoms associated with menopause, occurring in more than 75% of postmenopausal women. They are especially problematic in breast cancer patients since some breast cancer therapies can induce hot flashes. For mild hot flashes, it is proposed that behavioral modifications are the first step in management. Hormonal therapies, including estrogens and progestogens, are the most well known effective agents in relieving hot flashes; however, the safety of these agents is controversial. There is an increasing amount of literature on nonhormonal agents for the treatment of hot flashes. The most promising data regard newer antidepressant agents such as venlafaxine, which reduces hot flashes by about 60%. Gabapentin is another nonhormonal agent that is effective in reducing hot flashes. While many complimentary therapies, including phytoestrogens, black cohosh, and dehydroepiandrosterone, have been explored for the treatment of hot flashes; none can be recommended at this time. Furthermore, there is a lack of strong evidence to support exercise, yoga, or relaxation for the treatment of hot flashes. Paced respirations and hypnosis appear to be promising enough to warrant further investigation. Another promising nonpharmacological therapy, currently under investigation, involves a stellate ganglion block.
منابع مشابه
Managing Menopause: Current Therapeutic Options for Vasomotor Symptoms
enopause is an inevitable part of every woman’s life. Currently, 42 million women in the United States are over the age of 50 years and potentially menopausal. With the aging of the population, this number is expected to grow to 52 million by the year 2010. Physician familiarity with treatment options for symptoms associated with menopause will be a necessity. The definition of menopause is the...
متن کاملTreatment options for vasomotor symptoms in menopause: focus on desvenlafaxine
Vasomotor symptoms (VMS), including hot flashes and night sweats, occur in as many as 68.5% of women as a result of menopause. While the median duration of these symptoms is 4 years, approximately 10% of women continue to experience VMS as many as 12 years after their final menstrual period. As such, VMS have a significant impact on the quality of life and overall physical health of women exper...
متن کاملThe role of transdermal estrogen sprays and estradiol topical emulsion in the management of menopause-associated vasomotor symptoms
Vasomotor symptoms (VMS) are among the most bothersome complaints of postmenopausal women. To date, the most widely studied and effective treatment for VMS is hormone replacement therapy, consisting of estrogen (in women without a uterus) or estrogen plus progestin (in women with a uterus). Traditionally, oral estrogens have been used for treatment. However, over the years, additional estrogen ...
متن کاملThe vasomotor symptoms and skin changes in natural menopause among Iranian women
Introduction: Menopause is the most important event in middle-age. Women, in this period, face several changes. Vasomotor symptoms and skin changes are prevalent in the middle-age. This study, mainly, was performed identifying the vasomotor symptoms and skin changes in menopausal women. Materials and methods: Study sample was consisted of 150 women who have visited the healthcare centers, ...
متن کاملTreatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
OBJECTIVE To create an evidence-based position statement regarding the treatment of vasomotor symptoms associated with menopause. DESIGN The North American Menopause Society (NAMS) enlisted clinicians and researchers acknowledged to be experts in the field of menopause-associated vasomotor symptoms to review the evidence obtained from the medical literature and develop a document for final ap...
متن کامل